Geode Capital Management LLC recently announced the acquisition of new stake in INmune Bio Inc. (NASDAQ:INMB). The institutional investor has increased its shareholding in the Healthcare company by 1.00% to 0.14 million shares with purchase of 1382.0 shares. This fresh investment now brings its stake to 0.78% valued currently at $0.89 million. In addition, RBC Dominion Securities, Inc. raised its holdings by 8903.0 to 60009.0 shares. And UBS Financial Services, Inc. has lifted its position by 2.57% or 1000.0 shares – to 39950.0 shares.
With over 0.14 million INmune Bio Inc. (INMB) shares trading Friday and a closing price of $8.84 on the day, the dollar volume was approximately $1.21 million. The shares have shown a negative half year performance of -13.67% and its price on 01/13/23 gained nearly 12.61%. Currently, there are 17.95M common shares owned by the public and among those 11.66M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 2 analysts who have offered their price forecasts for INMB have a consensus price objective of $18.00. The analysts have set the share’s price value over the next 12 months at a high of $22.00 and a low of $14.00. The average price target is 50.89% above its recent price level and an upside to the estimated low will see the stock gain 36.86% over that period. But an upside of 59.82% will see the stock hit the forecast high price target while median target price for the stock is $18.00.
Insiders at the company have transacted a total of 7 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 7 of these insider trades were purchases, accounting for 99,900 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in INmune Bio Inc. are Vanguard Total Stock Market Index, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu. Vanguard Total Stock Market Index owns 0.36 million shares of the company’s stock, all valued at over $2.29 million. Fidelity Extended Market Index Fu now owns shares totaling to 0.33% of the shares outstanding.
Shares of INmune Bio Inc. (NASDAQ: INMB) opened at $7.77, down -$0.08 from a prior closing price of $7.85. However, the script later moved the day high at 8.94, up 12.61%. The company’s stock has a 5-day price change of 26.29% and 34.96% over the past three months. INMB shares are trading 39.43% year to date (YTD), with the 12-month market performance down to -0.90% lower. It has a 12-month low price of $4.63 and touched a high of $11.78 over the same period. INMB has an average intraday trading volume of 46.33K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 25.21%, 23.20%, and 13.83% respectively.
Institutional ownership of INmune Bio Inc. (NASDAQ: INMB) shares accounts for 10.70% of the company’s 17.95M shares outstanding. Mutual fund holders own 40.12%, while other institutional holders and individual stakeholders account for 6.64% and 4.08% respectively.
It has a market capitalization of $140.91M and a beta (3y monthly) value of 1.97. The earnings-per-share (ttm) stands at -$1.74. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.89% over the week and 7.03% over the month.
Analysts forecast that INmune Bio Inc. (INMB) will achieve an EPS of -$0.52 for the current quarter, -$0.77 for the next quarter and -$1.98 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.59 while analysts give the company a high EPS estimate of -$0.46. Comparatively, EPS for the current quarter was -$0.55 a year ago. Earnings per share for the fiscal year are expected to decrease by -86.40%, and -26.50% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 2 brokerage firm advisors rate INmune Bio Inc. (INMB) as a “Strong Buy” at a consensus score of 1.50. Specifically, 2 Wall Street analysts polled rate the stock as a buy, while 0 of the 2 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the INMB, a number of firms have released research notes about the stock. B. Riley Securities stated their Neutral rating for the stock in a research note on May 24, 2022, with the firm’s price target at $14-$7. Maxim Group coverage for the INmune Bio Inc. (INMB) stock in a research note released on July 07, 2021 offered a Buy rating with a price target of $42. B. Riley Securities was of a view on April 21, 2021 that the stock is Buy, while Maxim Group gave the stock Buy rating on January 22, 2021, issuing a price target of $16- $32. BTIG Research on their part issued Buy rating on September 01, 2020.